Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Treatment of Stage II-III Triple-positive Breast Cancer: a Phase II Clinical Trial

NCT04486911 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT04486911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04486911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Treatment of Stage II-III Triple-positive Breast Cancer: a Phase II Clinical Trial
Lead sponsor
Shengjing Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 27, 2020
Completion date
December 30, 2026
Enrollment
89 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer